One of Healis’ strategic priorities is developing the research of Dr. Eric Finzi, who first discovered the efficacy of BoNT/A neuromodulators for neuropsychiatric disorders. “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics. "We are thrilled to work with the world’s leading psychiatry researchers, bringing deep clinical expertise to Healis Therapeutics’ upcoming trial.”
“We are thrilled to be at the forefront of this field of research and could not have hoped for a better research partner than Mass. General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.